In an 89-year-old male admitted for discharge planning with multiple falls and currently on a twice-daily opioid 5 mg, should the opioid be switched to a transdermal buprenorphine patch to reduce sedation and fall risk, given that investigations for the falls were negative?

Switching to Buprenorphine Patch for Fall Prevention in an 89-Year-Old

Yes, switching from the current twice-daily opioid to a buprenorphine transdermal patch is strongly recommended for this 89-year-old patient with multiple falls, as buprenorphine causes less cognitive impairment and has been safely used in older adults, making it particularly appropriate when fall risk is a concern 1.

Rationale for the Switch

Why Buprenorphine is Superior in This Context

The 2025 NCCN guidelines explicitly state that buprenorphine "may cause less cognitive impairment and has been safely used in older adults" 1. This is critical for your patient given the multiple falls with negative workup—suggesting the falls may be medication-related rather than from an identifiable medical cause.

Key advantages specific to elderly patients with fall risk:

• Ceiling effect for respiratory depression - reduces risk of oversedation 1
• Less cognitive impairment compared to full mu-opioid agonists 1
• No dose adjustment needed for renal insufficiency - common in 89-year-olds 1
• Lower constipation risk - reducing straining/Valsalva that can cause falls 1
• Once-weekly dosing - eliminates peak-trough fluctuations that may contribute to unsteady gait 2

An international expert panel specifically identified buprenorphine as the "top-line choice for opioid treatment in the elderly" due to its safety profile in patients with organ dysfunction 3.

Practical Implementation

Starting Dose

Begin with buprenorphine transdermal 5 mcg/hour patch, changed every 7 days 1. This is the recommended starting dose for opioid-naïve patients and can be safely initiated in elderly patients 1.

Conversion Strategy

Since your patient is on a low-dose twice-daily opioid (appears to be 5 mg BD of an unspecified opioid):

1. Continue the current opioid at reduced dose initially while applying the first buprenorphine patch
2. Taper the previous opioid over 3-5 days as buprenorphine reaches steady state (takes 2-3 days) 1
3. Provide immediate-release opioid for breakthrough pain during transition 1

Titration

• Wait minimum 72 hours between dose increases 1
• Increase by 5 mcg/hour increments if needed 1
• Maximum dose 20 mcg/hour (higher doses only for opioid-tolerant patients) 1

Critical Monitoring Points

Fall Risk Assessment During Transition

Monitor closely during the first 2 weeks:

• Days 1-3: Highest risk as both medications may overlap
• Days 4-7: As previous opioid clears, assess for adequate analgesia
• Week 2: Steady-state achieved; reassess fall frequency

Common Pitfall to Avoid

Do NOT abruptly stop the current opioid when applying the first buprenorphine patch. Buprenorphine's partial agonist properties and high receptor affinity mean it can precipitate withdrawal if the patient has significant opioid tolerance, though at 5 mg BD this risk is lower 1, 4.

Watch for End-of-Dose Failure

Recent evidence shows some patients experience wearing-off effects by day 5-6 of the patch 5, 6. If pain increases or falls recur toward the end of the dosing interval, consider changing patches every 5 days instead of 7 days 5.

Additional Safety Considerations

QTc Monitoring

Buprenorphine can prolong QTc interval, though less than methadone 1. Obtain baseline ECG given the patient's age and check if on other QT-prolonging medications. Maximum dose is limited to 20 mcg/hour partly due to QTc concerns 1.

Medication Reconciliation

Review all medications for:

• CNS depressants (benzodiazepines, gabapentinoids, sedating antihistamines) - increase fall risk synergistically
• Anticholinergics - worsen cognitive effects
• Antihypertensives - may cause orthostatic hypotension contributing to falls

Renal Function

A major advantage: no dose adjustment needed even with severe renal impairment 1, 3. This distinguishes buprenorphine from morphine, oxycodone, and hydromorphone, which accumulate toxic metabolites in renal dysfunction common at age 89.

Expected Outcomes

Based on large observational studies, expect:

• Pain intensity reduction from baseline by approximately 50-60% 7
• Improved functionality and daily activities 8
• Better tolerability than previous full agonist opioids 2
• Stable plasma levels eliminating peak sedation that contributes to falls 2, 9

The transdermal formulation provides constant analgesia without the sedation peaks seen with twice-daily oral dosing, directly addressing your fall-prevention goal 2.